Market Overview

What Approval For Generic Copaxone Means For Mylan

What Approval For Generic Copaxone Means For Mylan
Related MYL
Drug Companies To Disclose Pricing Information In Ads
Bulls & Bears Of The Week: GE, Netflix, Nike, Twitter And More
Mylan launches generic version of Pfizer's Depo-Provera (Seeking Alpha)

Shares of Mylan N.V. (NASDAQ: MYL) traded higher by more than 13 percent Wednesday morning after the U.S. Food and Drug Administration granted approval for the company's generic version of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s Copaxone.

Copaxone, a therapy that is intended to prevent the relapse of multiple sclerosis, is the most prescribed treatment for relapsing forms of MS with sales in the billions, PharmaTimes reported. The approval of Mylan's generic version of Copaxone was widely expected by Wall Street analysts, although many experts disagreed on the exact timing of approval.

Shares of Teva were trading lower by more than 13 percent in reaction to a new competitor entering the market.

The approval of Mylan's generic therapy is "important" for the stock, Citi's Liav Abraham commented in a brief report. The approval will not only offer visibility towards upside to estimates but validates Mylan's pipeline, especially in complex generics. In fact, the approval will also "lend investor credibility" to other complex products in the pipeline, including generic Advair, Estrace cream, Restasis, and biosimilar products.

Finally, given Teva's sales of Copaxone in the U.S. stands at around $3.8 billion annually, the financial impact on Mylan "is not immaterial," the analyst concluded.

Related Links:

Playing The US Pharma Space: Buy Portola, Hold Corvus, Sell Teva

The Prescription For Generic Drugs ETF

Latest Ratings for MYL

Oct 2018Morgan StanleyDowngradesOverweightEqual-Weight
Oct 2018MizuhoDowngradesBuyNeutral
Aug 2018RBC CapitalUpgradesSector PerformOutperform

View More Analyst Ratings for MYL
View the Latest Analyst Ratings

Posted-In: CitiAnalyst Color News Health Care FDA Top Stories Analyst Ratings General Best of Benzinga


Related Articles (MYL + TEVA)

View Comments and Join the Discussion!

Latest Ratings

SBEvercore ISI GroupUpgrades4.5
PTIRBC CapitalUpgrades0.0
GPSJP MorganDowngrades24.0
GIIIB. Riley FBRUpgrades47.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

The Market In 5 Minutes: Yahoo's 2013 Data Breach Affected All 3 Billion Users

25 Stocks Moving In Wednesday's Pre-Market Session